NA
BOLT icon

NewEdge Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

NewEdge Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.74K Buy
+2,530
New +$11.9K ﹤0.01% 3543
2025
Q3 		– Sell
-483
Closed -$2.79K – 4113
2025
Q2 		$2.79K Buy
+483
New +$3.2K ﹤0.01% 3555

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NewEdge Advisors's BOLT Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Bolt Biotherapeutics (BOLT) in Q2 2026: 2,530 shares worth $9.74K. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in BOLT as recently as Q2 2025.

NewEdge Advisors first reported a position in BOLT in Q2 2025 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • NewEdge Advisors held 2,530 shares of Bolt Biotherapeutics worth $9.74K as of Q2 2026.
  • Bolt Biotherapeutics was a new NewEdge Advisors position in Q2 2026.
  • Bolt Biotherapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3543 holding.
  • NewEdge Advisors first reported a position in Bolt Biotherapeutics in Q2 2025 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.